Showing results (1-10 of 25) with videos related to
Sort By:
Pageof 3
Current Opinion in Drug Discovery & Development|February 1, 2006
The state-of-the-art in predictive toxicogenomicsMark R Fielden, Kyle L KolajaExpert Opinion on Drug Safety|March 8, 2008
The role of early in vivo toxicity testing in drug discovery toxicologyMark R Fielden, Kyle L KolajaToxicological Sciences : an Official Journal of the Society of Toxicology|June 15, 2007
A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicalsMark R Fielden, Richard Brennan, Jeremy GollubRegulatory Toxicology and Pharmacology : RTP|June 17, 2014
Evaluation of genotoxicity testing of FDA approved large molecule therapeuticsSatin G Sawant, Mark R Fielden, Kurt A BlackEnvironmental and Molecular Mutagenesis|February 21, 2020
Biomarkers of genome instability in normal mammalian genomes following drug-induced replication stressSheroy Minocherhomji, Yang Liu, Yudong D He, et al.American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice|June 15, 2005
Preclinical drug safety analysis by chemogenomic profiling in the liverMark R Fielden, Cecelia Pearson, Richard Brennan, et al.Toxicology Letters|July 18, 2002
Normal mammary gland morphology in pubertal female mice following in utero and lactational exposure to genistein at levels comparable to human dietary exposureMark R Fielden, Cora J Fong, Sandra Z Haslam, et al.Molecular Pharmacology|March 1, 2007
Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitroWenyue Hu, Claudio Sorrentino, Michael S Denison, et al.Critical Reviews in Toxicology|April 16, 2002
In silico approaches to mechanistic and predictive toxicology: an introduction to bioinformatics for toxicologistsMark R Fielden, Jason B Matthews, Kirsten C Fertuck, et al.Pageof 3